Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.67 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL10849765 | 0.98 | TAAR1 (0.65) | TAAR1ESR1ESR2HTR1AADRA2A | |
| SCHEMBL13372830 | 0.90 | TAAR1 (0.80) | TAAR1HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL11411805 | 0.83 | ESR1 (0.52) | TAAR1ESR1ESR2HTR1AADRA2A | |
| SCHEMBL11295562 | 0.82 | TAAR1 (0.69) | TAAR1HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL11290384 | 0.81 | TAAR1 (0.67) | TAAR1HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL177767 | 0.81 | TAAR1 (0.67) | TAAR1HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL8210853 | 0.81 | TAAR1 (0.67) | TAAR1HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL4033056 | 0.81 | TAAR1 (0.67) | TAAR1HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL3645596 | 0.81 | TAAR1 (0.67) | TAAR1HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL2870029 | 0.81 | TAAR1 (0.67) | TAAR1HTR1AADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103113386-B | Nitrogen heterocyclic substituted-dihydro artemisinin derivative and application thereof | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2015-12-23 | — | — | CN | disclosed |
| CN-103113386-A | Nitrogen heterocycle substituting dihydroartemisinin derivative and application thereof | UNIV SHENYANG PHARMACEUTICAL | 2013-05-22 | — | — | CN | disclosed |
| US-6958353-B2 | Imidazole derivatives or salts thereof and drugs containing the derivatives or the salts | HISAMITSU MEDICAL CO., LTD. (JP) | 2005-10-25 | — | — | US | disclosed |
| US-20030207896-A1 | Imidazole derivatives or salts thereof and drugs containing the derivatives or the salts | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2003-11-06 | — | — | US | disclosed |
| EP-1295880-A1 | IMIDAZOLE DERIVATIVES OR SALTS THEREOF AND DRUGS CONTAINING THE DERIVATIVES OR THE SALTS | SSP Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
| US-20020035092-A1 | Inhibit binding of alpha-v integrins to their ligands, use in treatment of immune and inflammatory disorders; 3-(4-(2-Aminoethyl)benzamide)-3-(2-(4-(2-pyridylamino)methyl) phenoxy)-4-pyrimidinyl)propanoic acid | CELLTECH THERAPEUTICS LIMITED | 2002-03-21 | — | — | US | disclosed |
| US-6319922-B1 | ALPHA-PYRIMIDYL-SUBSTITUTED; USEFUL FOR TREATING DISEASES INCLUDING INFLAMMATORY DISEASES, AND DISEASES INVOLVING ANGIOGENESIS, BONE RESORPTION OR CELLULAR OR MATRIX OVER-EXPANSION. | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-11-20 | — | — | US | disclosed |
| US-4006243-A | FUNGICIDE, BACTERICIDE, YEAST | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207896-A1 | Imidazole derivatives or salts thereof and drugs containing the derivatives or the salts | IL6, NOS1, NOS2 | TAAR1 1150/4885ESR1 3060/4885ESR2 2014/4885 |
| US-20020035092-A1 | Inhibit binding of alpha-v integrins to their ligands, use in treatment of immune and inflammatory disorders; 3-(4-(2-Aminoethyl)benzamide)-3-(2-(4-(2-pyridylamino)methyl) phenoxy)-4-pyrimidinyl)propanoic acid | ITGA1, ITGB1, VCAM1 | TAAR1 865/4885ESR1 3012/4885ESR2 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.